Lyell Immunopharma (NASDAQ:LYEL) Share Price Breaks Below 50 Day Moving Average – What’s Next?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $10.85 and traded as low as $10.58. Lyell Immunopharma shares last traded at $10.77, with a volume of 78,055 shares.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating on shares of Lyell Immunopharma in a report on Friday, September 11th. Citigroup reaffirmed a “market outperform” rating on shares of Lyell Immunopharma in a report on Friday, August 14th. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday, October 25th. B. Riley Financial began coverage on shares of Lyell Immunopharma in a research report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 price objective for the company. Finally, Stifel Nicolaus assumed coverage on shares of Lyell Immunopharma in a research note on Thursday, August 6th. They issued a “buy” rating and a $36.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Lyell Immunopharma currently has an average rating of “Moderate Buy” and an average price target of $40.86.

Lyell Immunopharma Stock Down 1.0%

The company has a market cap of $263.87 million, a price-to-earnings ratio of -0.84 and a beta of -0.04. The firm has a 50 day moving average price of $10.85 and a two-hundred day moving average price of $16.77.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. On average, equities analysts expect that Lyell Immunopharma, Inc. will post -7.16 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Velan Capital Investment Management LP boosted its position in shares of Lyell Immunopharma by 2.9% during the 2nd quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock valued at $1,475,000 after purchasing an additional 3,000 shares in the last quarter. Walleye Capital LLC acquired a new stake in Lyell Immunopharma during the first quarter worth approximately $445,000. Squarepoint Ops LLC grew its stake in Lyell Immunopharma by 119.4% during the second quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock worth $595,000 after purchasing an additional 23,028 shares during the period. Bank of New York Mellon Corp acquired a new stake in Lyell Immunopharma during the second quarter worth approximately $347,000. Finally, Bank of America Corp DE increased its holdings in Lyell Immunopharma by 314.2% in the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock worth $668,000 after purchasing an additional 25,276 shares in the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.